$KULR

KULR Technology Group, Inc. (KULR): Results of Operations and Financial Condition

KULR Technology Group, Inc. (KULR) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001662684 0001662684 2026-08-13 2026-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earli

Original reporting
Published Aug 13, 2026, 8:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$KULR
Neutral
medium confidence
Mentioned
$KULR
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$KULRNeutralMed
01

Why it matters

The filing signals that updated quarterly financial information is available to the market, which can affect valuation and positioning for the next earnings cycle.

02

Market read

This is a scheduled quarterly reporting disclosure, but the excerpt does not include the actual financial metrics, so the tradable edge depends on Exhibit 99.1 details.

03

What to watch

Traders should focus on cash flow, gross margin, backlog or contract momentum (if disclosed), and any forward-looking statements in Exhibit 99.1, since the excerpt provides none of these.

Relevance 7/10Novelty 6/10Timing: filed Aug 13, 2026, after the company issued its Q2 2026 results press release

Background

KULR submitted an SEC Form 8-K under Item 2.02 to furnish its Q2 2026 results press release as Exhibit 99.1.

Company-level read

Ticker impact

$KULRNeutralMedium confidence
Context

KULR filed an 8-K stating it issued a press release with Q2 2026 financial results for the quarter ended June 30, 2026.

Expected impact

Potential volatility around the release details in Exhibit 99.1, but direction depends on the specific Q2 numbers and any guidance included there.

Evidence & confidence

The 8-K itself only confirms the existence of the Q2 results press release (Exhibit 99.1) without providing the figures in the scraped text, so the magnitude and direction cannot be determined from this excerpt alone.

Market effects

Limited from the excerpt; any sector read-through would depend on the specific Q2 performance and cash burn in Exhibit 99.1.

None indicated in the provided text.

None indicated in the provided text.

Counterpoint

If Exhibit 99.1 contains no guidance changes and results are broadly in line, the market reaction may be muted despite the filing.

Key entities

  • KULR Technology Group, Inc.

    Issuer filing the 8-K and furnishing Q2 2026 results via Exhibit 99.1.

  • SEC Form 8-K

    Current report used to furnish the company’s quarterly results press release.

Related articles

$KULRMed

KULR Technology Group, Inc. (KULR): Completion of Acquisition or Disposition of Assets

KULR Technology Group, Inc. (KULR) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. false 0001662684 0001662684 2026-07-20 2026-07-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earli

$BKSYMed

BlackSky (BKSY) Q2 2026 Earnings Call Transcript

BlackSky (BKSY) discussed its Q2 2026 earnings call, citing Gen-3 satellite performance and Spectra AI platform. It reported Q2 total revenue up 50% year over year, adjusted EBITDA margin of 14% on $33 million revenue, and $200 million year-to-date bookings. The company raised $150 million, boosting liquidity above $325 million, and said Gen-3 related products drove 90% of growth.

$CRMDMed

CorMedix Q2 Earnings Call Highlights

CorMedix (NASDAQ:CRMD) reported Q2 revenue rising to $39.7M from $39.7M a year earlier, with 2026 including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M ($0.33 basic). It reaffirmed 2026 revenue guidance of $325M-$345M and raised adjusted EBITDA to $125M-$140M. REZZAYO supplemental NDA is planned for Q3 2026, with FDA action expected H1 2027.

$CLBTMed

Cellebrite (CLBT) Stock Rebounds As ARR Grows But Outlook Cools

Simply Wall St reports Cellebrite (CLBT) shares rose about 3% after results despite a prior 30% drop. Q2 revenue was US$131.1m (up from US$113.3m), while ARR was US$508m (up from US$420m). Management raised full-year adjusted EBITDA margin guidance to the high 20s but trimmed ARR outlook to US$550m to US$560m.

$CLXMed

Are Wall Street Analysts Predicting Clorox Stock Will Climb or Sink?

The article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.